Patent ID: 11878055
Assignee: BIONTECH SE
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 25:
26. A composition comprising at least one unit dose of LNP-encapsulated RNA molecules, wherein the composition comprises:
a population of LNPs encapsulating RNA molecules, wherein:
the LNPs comprise an ionizable cationic lipid, a neutral lipid, a sterol, and a PEG-modified lipid in molar ratios of 20-60%, 5-25%, 25-55%, and 0.5-15%, respectively; and
each LNP in the population encapsulates at least an RNA molecule, wherein the RNA molecule comprises
(a) a nucleotide sequence that is at least 99% identical to SEQ ID NO: 161; or
(b) a nucleotide sequence that is at least 95% identical to SEQ ID NO: 161, and which comprises a nucleotide sequence that encodes a SARS-CoV-2 protein comprising the following substitutions relative to SEQ ID NO: 1: T19I, Δ24-26, A27S, V83A, G142D, Δ145, H146Q, Q183E, V213E, G252V, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478K, E484A, F486P, F490S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K, K986P, and V987P;
(b) N1-methyl-pseudouridine in place of each uridine; and
(c) a 5′ cap that comprises m27,3′-OGppp(m12′-O)ApG.